Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion moved earlier from Dec 1, 2026 to Nov 1, 2026
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 11 of 11 entries
  2. Enrollment closed, study ongoing
    • Final enrollment: 197 participants (planned 240)
    • Primary and study completion moved earlier from Dec 31, 2026 to Dec 1, 2026
    • Site details revised
    v6
  3. Start date: Apr 1, 2025 to Apr 3, 2025v5
  4. Re-verified, no change to tracked fieldsv4
  5. Primary and study completion dates: Sep 30, 2026 to Dec 31, 2026
    • Start date changed from estimate of Jun 30, 2025 to Apr 1, 2025
    v3
  6. Start date: Apr 30, 2025 to Jun 30, 2025v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).
Trial Details
NCT Number NCT06910670
Lead Sponsor Washington University School of Medicine
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Cholangiocarcinoma, Colorectal Cancer, Multiple Myeloma
Related terms Cholangiocarcinoma, Colorectal Neoplasms, Multiple Myeloma
Enrollment 197 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov